Recently (September 16), Shanghai Roche Pharmaceutical Co.
According to the data query of Yaozhi, the domestic sample hospital sales of polyethylene glycol interferon α-2a injection reached 4.
Not long ago, pharmaceutical giant Roche released the first half of 2022 results
125 years, the history of the development of the Roche Empire
In Basel, Switzerland in 1896, Roche, the world's three major pharmaceutical giants that had been on a par with Johnson & Johnson and Pfizer for many years, were rising
In the subsequent development process, Roche ushered in three real "highlight moments"
What made Roche the first big bucket of gold and made a name for himself was vitamins
After World War II, in order to get rid of excessive dependence on vitamins, Roche began to strengthen the research and development
What makes today's giant Roche is the acquisition
In the past 125 years, Roche has turned his rudder head again and again in storms and sailed into a safe haven, which can be called a rare "immortal bird"
The new troika took shape
The performance revenue of Roche's super heavy oncology product "Troika" has always attracted much attention
Now how will Roche lay out the inheritance highlights? According to the financial report, Roche's pharmaceutical business has strong
The growth of 2022H1 is mainly driven by the new leading second-generation CD20 antibody Ocrevus (Ocrevizumab), the targeted HER2 drug Perjeta (pertuzumab) and the hemophilia drug Hemlibra (Emilymab), with sales of nearly 6.
Ocevus (Orizumab), as the world's first glycosylated type II anti-CD20 monoclonal antibody, directly induces B cell death
Perjeta (pertuzumab) is a monoclonal antibody drug developed by Roche's Gentec for HER2 targets, which was approved by the FDA in 2012
Hemlibra is the world's second bispecific antibody that innovatively pulls IXa and X factors together to mimic the effects of
In addition to the above blockbuster products, the field of oncology as the top priority of Roche's layout, there are currently 72 research and development pipelines, involving a variety of technology platforms, including small molecules, monoclonal antibodies, double antibodies, fusion proteins, ADC therapy, etc
Among them, Tecentriq (altelizumab), which is considered by most people in the industry to be one of the potential of the "new troika", is a drug targeting PDL1, and its growth rate (+11%) is significantly slower than that of the same period last year (+29%), with revenues of 1.
758 billion Swiss francs
.
In addition, Roche has approved 2 drugs for marketing in the first half of 2022, namely the US FDA's approval of VEGF-A/Ang2 double anti-Vabysmo (faricimab-svoa) for the treatment of wet or neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME); The European Union has approved CD20/CD3 biantibody Lunsumio (mosunetuzumab) for the marketing of adult patients with
recurrent or refractory (R/R) follicular lymphoma (FL) who have undergone at least two previous systemic treatments.
In addition, the new indication for Evrysdi (risperan) has also been approved by the FDA for the treatment of children
with spinal muscular atrophy (SMA) under 2 months.
Evrysdi is the first approved RNA-targeting small molecule drug, unveiling the advent
of RNA-targeting small molecule drugs by directly targeting RNA or RNA-protein complexes.
It is worth mentioning that this drug is also the first and only SMA therapy
that can be used at home.
In the second half of 2022, a number of products are expected to be listed in China
Shortly after the financial report was announced, on July 29, Roche's "unlimited cancer" therapy "emtricitinib" was approved in China for the treatment of NTRK fusion-positive locally advanced or metastatic solid tumors
.
This introduction to China has brought new treatment options
to patients who have been waiting for a long time.
According to Roche's public information, as of the end of December 2021, it has accelerated the introduction of more than 40 indications for 18 Roche global innovative drugs into China
.
At present, Roche has submitted 5 drugs for listing in China, and it is expected to be approved for listing in 2022
.
Trastuzumab injection (subcutaneous) is a subcutaneous Herceptin that was approved in the United States in February 2019 for use in patients with
HER2-positive early stage breast cancer.
This new dosage form therapy is a ready-to-use formulation that can be administered in 2 to 5 minutes, while intravenous Herceptin takes 30 to 90 minutes
.
In April 2021, the new drug marketing application of trastuzumab injection (subcutaneous injection) was accepted by
CDE.
Polatuzumab vedotin is an ADC product that targets CD79b
.
By specifically binding to CD79b on tumor cells, it delivers anticancer drugs to kill these B cells and is able to reduce damage
to normal cells.
In China, vibrotizumab submitted a number of new drug marketing applications in December 2021 and were accepted by CDE, and its applications for the treatment of adult patients with relapsed or refractory DLBCL were also included in the CDE for priority review
.
Pittozumab/Trastuzumab Injection (Subcutaneously) is a fixed-dose combination of subcutaneous preparations containing pittozumab, trastuzumab, and hyaluronidase
.
The product can complete the administration of patuzumab and trastuzumab in a faster manner within 5 to 8 minutes compared to the hours of standard intravenous administration
.
Previously, the drug has been approved in the United States, the European Union and other countries and regions (trade name Phesgo) for the treatment of early and metastatic HER2-positive breast cancer patients
.
In China, Roche is currently conducting a Phase 3 clinical trial
of the product for the treatment of HER2-positive early-stage breast cancer.
On July 27, the new drug listing application for the drug was accepted
by CDE.
Crovalimab (RG6107) is a new generation C5 complement inhibitor that blocks the cleavage of complement C5 to C5a and C5b, inhibiting complement activation
.
Previously, the drug has been included in the breakthrough treatment variety and priority review
in China.
On August 10, Roche announced that crovalimab's application for a new drug for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) has been accepted
by CDE.
Vabysmo (faricimab) is a bispecific antibody
that targets Ang-2 and VEGF-A.
In China, Roche is currently carrying out a number of Phase 3 clinical trials of the product, with indications covering DME, macular edema secondary to retinal branch vein obstruction, neovascular age-related macular degeneration, central retinal vein obstruction or macular edema secondary to hemilateral retinal vein occlusion
.
On August 10, faricimab's new drug listing application was accepted
by CDE.
In addition to the above-mentioned drugs that have been declared for listing, the company also has a number of new drugs under development that have not been approved in China that are currently undergoing Phase 3 clinical trials in China, and they also represent the next wave of innovative drugs
that Roche is expected to be approved in China.
We look forward to seeing these drugs on the market in the future for the benefit of patients around the
world.
"
If this article infringes on your rights, please contact us
.
